PHIO
Phio Pharmaceuticals Corp.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
0.99
▲ 0.00 (0.30%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.99
Day high
1.02
Day low
0.97
Volume
131.77K
Market cap
$11.55M
P/E (TTM)
—
52W range
0.81 – 4.19
Trailing performance
Returnvs SPY
1W
-3.50%
-5.4%
1M
-7.96%
-9.1%
3M
-7.96%
-12.5%
6M
-19.84%
-38.0%
YTD
-5.33%
-19.6%
1Y
-58.41%
-74.8%
3Y
-92.69%
-174.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PHIO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
930.89K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | PLOTT RONALD TODD Director |
BUY | 10.00K | $10.35K | Direct |
| Sep 28, 26 | BITTERMAN ROBERT J Chief Executive Officer |
STOCK | 400.00K | $0 | Direct |
| Sep 28, 26 | PLOTT RONALD TODD Director |
STOCK | 17.00K | $0 | Direct |
| Sep 28, 26 | CARSON LISA CABOTT Chief Financial Officer |
STOCK | 108.00K | $0 | Direct |
| Sep 22, 26 | BITTERMAN ROBERT J Chief Executive Officer |
BUY | 2.00K | $2.06K | Direct |
| Sep 15, 26 | BRADFORD PATRICIA A Director |
BUY | 12.00K | $12.36K | Direct |
| Aug 19, 26 | PLOTT RONALD TODD Director |
BUY | 15.00K | $17.10K | Direct |
| Aug 18, 26 | BITTERMAN ROBERT J Chief Executive Officer |
BUY | 10.00K | $10.60K | Direct |
| Jun 26, 26 | BITTERMAN ROBERT J Chief Executive Officer |
BUY | 10.00K | $9.90K | Direct |
| Feb 5, 26 | BITTERMAN ROBERT J Chief Executive Officer |
STOCK | 120.00K | $0 | Direct |
| Feb 5, 26 | BRADFORD PATRICIA A Director |
STOCK | 18.50K | $0 | Direct |
| Feb 5, 26 | LOCKSHIN CURTIS Director |
STOCK | 16.60K | $0 | Direct |
| Feb 5, 26 | DEMING DAVID H Director |
STOCK | 23.80K | $0 | Direct |
| Feb 5, 26 | FREEMAN JONATHAN E PH.D. Director |
STOCK | 16.60K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BITTERMAN ROBERT J |
Chief Executive Officer | 764.87K | Stock Award(Grant) |
BRADFORD PATRICIA A |
Director | 57.65K | Purchase |
CARSON LISA CABOTT |
Chief Financial Officer | 189.11K | Stock Award(Grant) |
DEMING DAVID H |
Director | 37.80K | Stock Award(Grant) |
FERRARA ROBERT L |
Director | 38.67K | Stock Award(Grant) |
FREEMAN JONATHAN E PH.D. |
Director | 32.66K | Stock Award(Grant) |
LOCKSHIN CURTIS |
Director | 35.16K | Stock Award(Grant) |
PLOTT RONALD TODD |
Director | 42.00K | Purchase |
Fundamentals
Market cap$11.55M
Enterprise value$-1.44M
Revenue (TTM)—
Gross profit$-8.53M
EBITDA$-13.47M
Net income$-12.90M
EPS (TTM)$-1.29
Free cash flow$-7.72M
Total cash$13.00M
Total debt$0
Book value / share$1.09
Shares outstanding11.62M
Float11.26M
Short % of float1.30%
Dividend yield0.00%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.63
PEG ratio—
Price / sales—
Price / book0.92
EV / revenue—
EV / EBITDA0.11
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-113.71%
Return on assets-65.77%
Debt / equity—
Current ratio8.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $4.62M | $3.64M | $6.33M | $7.01M | — | +26.8% |
| Selling, general & admin | $4.60M | $3.74M | $4.37M | $4.45M | — | +22.9% |
| Total operating expense | $9.22M | $7.39M | $10.70M | $11.46M | — | +24.8% |
| Operating income | -$9.22M | -$7.39M | -$10.70M | -$11.46M | — | -24.8% |
| Net interest income | $520.00K | $231.00K | -$8.00K | — | -$9.00K | +125.1% |
| Pre-tax income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | — | -21.7% |
| Tax provision | — | — | — | $0 | $0 | — |
| Net income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | — | -21.7% |
| Net income to common | -$8.70M | -$7.15M | -$10.83M | -$11.48M | — | -21.7% |
| Basic EPS | -1.45 | -9.08 | -46.76 | -90.86 | — | +84.0% |
| Diluted EPS | -1.45 | -9.08 | -46.76 | -90.86 | — | +84.0% |
| EBIT | -$9.22M | -$7.39M | -$10.70M | -$11.46M | — | -24.8% |
| EBITDA | -$9.22M | -$7.35M | -$10.51M | -$11.27M | — | -25.4% |
| Basic shares | 5.98M | 787.47K | 231.51K | 126.33K | — | +659.9% |
| Diluted shares | 5.98M | 787.47K | 231.51K | 126.33K | — | +659.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.03M | $5.38M | $8.49M | $11.78M | — | +290.8% |
| Cash & short-term investments | $21.03M | $5.38M | $8.49M | $11.78M | — | +290.8% |
| Total current assets | $21.48M | $5.74M | $9.32M | $12.45M | — | +274.4% |
| Property, plant & equipment | $11.00K | $2.00K | $39.00K | $344.00K | — | +450.0% |
| Total assets | $21.49M | $5.74M | $9.36M | $12.81M | — | +274.5% |
| Total current liabilities | $1.34M | $1.01M | $1.63M | $1.94M | — | +32.0% |
| Total debt | — | $0 | $35.00K | $170.00K | $295.00K | — |
| Total liabilities | $1.34M | $1.01M | $1.63M | $1.98M | — | +32.0% |
| Retained earnings | -$155.05M | -$146.36M | -$139.21M | -$128.38M | — | -5.9% |
| Shareholder equity | $20.15M | $4.72M | $7.73M | $10.84M | — | +326.6% |
| Working capital | $20.14M | $4.72M | $7.69M | $10.51M | — | +326.5% |
| Net tangible assets | $20.15M | $4.72M | $7.73M | $10.84M | — | +326.6% |
| Shares issued | 11.62M | 1.73M | 416.37K | 126.56K | — | +570.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | -21.7% |
| Depreciation & amortisation | $3.00K | $35.00K | $184.00K | $193.00K | -91.4% |
| Stock-based compensation | $481.00K | $147.00K | $303.00K | $414.00K | +227.2% |
| Change in working capital | $235.00K | -$138.00K | -$536.00K | -$1.26M | +270.3% |
| Operating cash flow | -$7.98M | -$7.11M | -$10.75M | -$12.13M | -12.2% |
| Capital expenditure | -$12.00K | -$1.00K | -$5.00K | -$121.00K | -1,100.0% |
| Investing cash flow | -$12.00K | $8.00K | -$5.00K | -$121.00K | -250.0% |
| Share buybacks | $0 | -$1.00K | -$13.00K | $0 | +100.0% |
| Financing cash flow | $23.64M | $4.00M | $7.41M | -$26.00K | +491.6% |
| Free cash flow | -$7.99M | -$7.11M | -$10.75M | -$12.25M | -12.3% |
| End cash position | $21.03M | $5.38M | $8.49M | $11.83M | +290.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $3.08M | $2.79M | $1.48M | $1.18M | $1.07M | — | +10.3% |
| Selling, general & admin | $1.19M | $1.37M | $1.06M | $1.32M | $1.24M | — | -13.7% |
| Total operating expense | $4.27M | $4.17M | $2.53M | $2.50M | $2.31M | — | +2.4% |
| Operating income | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | — | -2.4% |
| Net interest income | $130.00K | $161.00K | $163.00K | $113.00K | $143.00K | — | -19.3% |
| Pre-tax income | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | — | -3.4% |
| Net income | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | — | -3.4% |
| Net income to common | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | — | -3.4% |
| Basic EPS | -0.36 | -0.34 | — | -0.44 | -0.45 | -0.41 | -5.9% |
| Diluted EPS | -0.36 | -0.34 | — | -0.44 | -0.45 | -0.41 | -5.9% |
| EBIT | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | — | -2.4% |
| EBITDA | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | — | -2.4% |
| Basic shares | 11.62M | 11.62M | — | 5.47M | 4.79M | 4.31M | 0.0% |
| Diluted shares | 11.62M | 11.62M | — | 5.47M | 4.79M | 4.31M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | -23.7% |
| Cash & short-term investments | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | -23.7% |
| Total current assets | $14.30M | $17.40M | $21.48M | $11.49M | $11.29M | -17.8% |
| Property, plant & equipment | $9.00K | $10.00K | $11.00K | $12.00K | $7.00K | -10.0% |
| Total assets | $14.31M | $17.41M | $21.49M | $11.51M | $11.30M | -17.8% |
| Total current liabilities | $1.71M | $950.00K | $1.34M | $1.67M | $1.21M | +79.5% |
| Total liabilities | $1.71M | $950.00K | $1.34M | $1.67M | $1.21M | +79.5% |
| Retained earnings | -$163.19M | -$159.06M | -$155.05M | -$152.68M | -$150.29M | -2.6% |
| Shareholder equity | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | -23.4% |
| Working capital | $12.59M | $16.45M | $20.14M | $9.83M | $10.09M | -23.5% |
| Net tangible assets | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | -23.4% |
| Shares issued | 11.62M | 11.62M | 11.62M | 5.78M | 4.80M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | — | -3.4% |
| Depreciation & amortisation | $1.00K | $1.00K | $1.00K | $2.00K | $0 | — | 0.0% |
| Stock-based compensation | $278.00K | $318.00K | $274.00K | $113.00K | $51.00K | — | -12.6% |
| Change in working capital | -$176.00K | -$316.00K | $17.00K | $192.00K | -$425.00K | — | +44.3% |
| Operating cash flow | -$4.04M | -$4.00M | -$2.08M | -$2.08M | -$2.54M | — | -0.8% |
| Capital expenditure | — | — | — | -$7.00K | -$3.00K | -$2.00K | — |
| Investing cash flow | $0 | $3.00K | $0 | -$7.00K | -$3.00K | — | -100.0% |
| Financing cash flow | $0 | $0 | $12.40M | $2.02M | $40.00K | — | — |
| Free cash flow | -$4.04M | -$4.00M | -$2.08M | -$2.09M | -$2.54M | — | -0.8% |
| End cash position | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | — | -23.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.36 | -0.36 | 0.0% |
| Mar 2026 | -0.24 | -0.34 | -44.7% |
| Dec 2025 | -0.47 | -0.15 | +68.1% |
| Sep 2025 | -0.44 | -0.44 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.36 | 2 | $0 | 0.0% |
| Next quarter | -0.39 | 2 | $0 | 0.0% |
| Current year | -1.45 | 2 | $0 | 0.0% |
| Next year | -0.61 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$14.00
High target$14.00
Low target$14.00
Implied upside1308.45%
Analyst count1
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders8.01%
Held by institutions10.21%
Institutions holding27
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.01
-1.49% from price
SMA 20
1.01
-1.92% from price
SMA 50
1.06
-6.21% from price
SMA 100
1.06
-6.04% from price
SMA 200
1.11
-10.14% from price
EMA 12
1.01
-1.50% from price
EMA 26
1.03
-3.39% from price
EMA 50
1.05
-5.01% from price
RSI (14)
41.1
Neutral
MACD (12,26,9)
-0.02
Hist -0.00
ATR (14)
0.06
5.54% of price
Realised vol 30D
34.4%
Annualised
Bollinger upper
1.04
20, 2σ
Bollinger lower
0.98
20, 2σ
50 / 200 cross
Death
1.06 vs 1.11
Trend bias
Below 200
-10.14%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.23
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
34.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.6%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.06
5.54% of price
Beta (reported)
0.84
5Y monthly, from filing
Short interest
Shares short
149.89K
Prior 319.75K
Change vs prior
-53.1%
Shorts covering
% of float
1.30%
Normal
% of shares out
1.29%
Against total outstanding
Days to cover
0.8
Liquid
Float
11.26M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 8, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 6, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 16, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJan 15, 2020
Last split1:9
Split dateJul 5, 2024
SEC filings
Offering Registrations
S-8 · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-09-14
Annual Report to Shareholders
ARS · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-21
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-04-08
Corporate Changes & Voting Matters
8-K · 2026-03-30
Headlines
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
TMX Newsfile · 21h ago
OTC Markets Group Announces Agenda for Third Annual Global Markets Forum, October 7th & 8th
GlobeNewswire · 2d ago
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
TMX Newsfile · 2d ago
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
TMX Newsfile · 14d ago
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
TMX Newsfile · 23d ago
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TMX Newsfile · 26d ago
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
TMX Newsfile · 57d ago
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
TMX Newsfile · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.